Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, multi-center trial to evaluate the
safety and efficacy of TJ003234 administered as an intravenous (IV) infusion in subjects with
severe COVID-19 under supportive care, and to assess the effect of TJ003234 on the levels of
cytokines.